- PHASE I
- PHASE II
- PHASE III
Samatasvir is an NS5A inhibitor which has demonstrated favorable safety and potent pan-genotypic activity in preclinical and clinical studies. Samatasvir is currently being evaluated as part of all-oral combination regimens for up to 12 weeks of treatment.
IDX21437 is Idenix’s lead next-generation uridine-based nucleotide prodrug which has shown favorable safety and potent, pan-genotypic activity in preclinical studies and in a 7-day monotherapy phase I/II clinical trial.
IDX21459 is a follow-on uridine-based nucleotide prodrug currently being evaluated in a phase I clinical trial in healthy volunteers and HCV-infected patients.
Idenix maintains robust research programs to identify and develop next-generation nucleotide polymerase prodrugs for HCV with a focus on follow-on nucleotide prodrugs and novel nucleotide prodrugs with complementary resistance profiles to those currently under development.